Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Lenabasum (Primary)
- Indications Diffuse scleroderma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms RESOLVE-1
- Sponsors Corbus Pharmaceuticals
- 15 Nov 2023 Results assessing the performance of Revised CRISS in a phase 3 clinical trial of lenabasum in early dcSSc at week 52 presented at the ACR Convergence 2023
- 26 Apr 2023 Results published in the Arthritis and Rheumatology
- 09 Nov 2021 Results presented at the ACR Convergence 2021